Published in Science · View the paper (DOI)
A new probiotic-guided chimeric antigen receptor (CAR)-T platform uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find and destroy tumor cells in situ. The approach expands the scope of CAR-T cell therapy to include solid tumors, which are poorly infiltrated by T cells.
Coverage from 2 institutions
- Engineered bacteria guide CAR-T cells to poorly infiltrated solid tumors American Association for the Advancement of Science (AAAS) · Oct 12, 2023 · first to report
- Engineered bacteria paint targets on tumors for cancer-killing T cells to see Columbia University School of Engineering and Applied Science · Oct 12, 2023